Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by trade2win2on Nov 28, 2012 8:28am
218 Views
Post# 20653068

Updated Reserves Report presented a 219% increase

Updated Reserves Report presented a 219% increase

CALGARY, ALBERTA--(Marketwire - Nov. 28, 2012) - Santa Maria Petroleum Inc. (TSX VENTURE:SMQ) ("Santa Maria" or the "Company") is pleased to announce that it has obtained an updated reserve evaluation of its oil and gas properties effective June 30, 2012 (the "Updated Reserves Report") as prepared by Petrotech Engineering Ltd. ("Petrotech"), an independent qualified reserves evaluator. Petrotech is the Company's independent qualified reserve evaluator for annual disclosure requirements. The Updated Reserves Report is an update to the reserve evaluation of the Company's oil and gas properties effective December 31, 2011 (the "2011 Report") as prepared by Petrotech and is based on the completion, testing and production of the Flami field in Block 27 and revisions to operating costs and reserve data for the Canaguay well in the Canaguaro field based on operations and production from January 1, 2012 to June 30, 2012.

A summary report is available for review on SEDAR at www.sedar.com.

The Updated Reserves Report presented a 219% increase to the Company's net proved and probable ("2P") heavy oil reserves and a 259% increase to the before-tax net present value of 2P reserves at a 10% discount rate as compared to the annual filing, effective December 31, 2011. All of the Company's reserves are located in Colombia. The Company only has heavy oil reserves.

Bullboard Posts